# US 2008/0188510 A1 · Novel methods using zonisamide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188510 A1
- Document ID: US20080188510A1
- Status: Published application
- Kind: A1
- Application number: 11/419,816
- Filed: 2006-05-23
- Published: 2008-08-07
- Earliest claimed: 2005-05-23
- Assignees: Eisai R&D Management Co., Ltd.
- Inventors: Hiroshi Yoshino
- Web page: https://patentgrep.com/patent/US20080188510A1

## CPC

- A61K 31/423: condensed with carbocyclic rings
- A61K 31/4355: the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to usefulness of zonisamide as a pharmaceutical composition for treating dementia or cognitive impairment.

## Claims

### Claim at position 1

1-2. (canceled)

### Claim 3

A method for treating dementia or cognitive impairment, comprising administering an effective amount of zonisamide, a salt thereof, a solvate thereof or a prodrug thereof to a patient in need of treatment for these diseases.

### Claim 4 (depends on 3)

A method according to claim 3, wherein the dementia or cognitive impairment is one selected from the group consisting of:
(a) Alzheimer's disease, senile dementia of the Alzheimer's type, dementia associated with vascular disease, dementia caused by vascular disease, dementia associated with Parkinson's disease, dementia associated with Huntington's disease, dementia associated with alcohol addiction, Lewy body dementia and AIDS dementia;
(b) mild cognitive impairment and age-related impaired memory;
(c) dementia and/or cognitive impairment associated with epilepsy, dementia and/or cognitive impairment associated with cerebral tumor, dementia and/or cognitive impairment associated with brain injury, dementia and/or cognitive impairment associated with multiple sclerosis, dementia and/or cognitive impairment associated with Down's syndrome, dementia and/or cognitive impairment associated with Rett's syndrome, dementia and/or cognitive impairment associated with progressive supranuclear palsy, dementia and/or cognitive impairment associated with frontal lobe syndrome, and dementia and/or cognitive impairment associated with neurologic and/or psychiatric conditiones; and
(d) cognitive impairment associated with traumatic brain injury, cognitive impairment associated with aftereffects of coronary-artery bypass surgery, cognitive impairment associated with electric shock therapy and cognitive impairment associated with chemotherapy.

### Claim 5 (depends on 3, 4)

A method according to claim 3 or 4, wherein the patient is human.

### Claim 6

A pharmaceutical composition comprising zonisamide, a salt thereof, a solvate thereof or a prodrug thereof together with at least one selected from the group consisting of cholinesterase inhibitors, NMDA receptor antagonists and AMPA receptor antagonists.

### Claim 7 (depends on 6)

A pharmaceutical composition according to claim 6, wherein the cholinesterase inhibitor is donepezil or a salt thereof.

### Claim 8 (depends on 6)

A pharmaceutical composition according to claim 6, wherein the cholinesterase inhibitor is donepezil hydrochloride.

### Claim 9 (depends on 6)

A pharmaceutical composition according to claim 6, wherein the cholinesterase inhibitor is galanthamine or a salt thereof.

### Claim 10 (depends on 6)

A pharmaceutical composition according to claim 6, wherein the NMDA receptor antagonist is memantine.

### Claim 11 (depends on 6)

A pharmaceutical composition according to claim 6, wherein the AMPA receptor antagonist is talampanel.

### Claim at position 11

12-13. (canceled)

### Claim 14

A method for treating dementia or cognitive impairment, comprising administering zonisamide, a salt thereof, a solvate thereof or a prodrug thereof together with at least one selected from the group consisting of cholinesterase inhibitors, NMDA receptor antagonists and AMPA receptor antagonists to a patient in need of treatment for these diseases.

### Claim 15 (depends on 14)

A method according to claim 14, wherein the cholinesterase inhibitor is donepezil or a salt thereof.

### Claim 16 (depends on 14)

A method according to claim 14, wherein the cholinesterase inhibitor is donepezil hydrochloride.

### Claim 17 (depends on 14)

A method according to claim 14, wherein the cholinesterase inhibitor is galanthamine or a salt thereof.

### Claim 18 (depends on 14)

A method according to claim 14, wherein the NMDA receptor antagonist is memantine.

### Claim 19 (depends on 14)

A method according to claim 14, wherein the AMPA receptor antagonist is talampanel.

### Claim 20 (depends on 14)

The method according to claim 14, wherein the dementia or cognitive impairment is one selected from the group consisting of:
(a) Alzheimer's disease, senile dementia of the Alzheimer's type, dementia associated with vascular disease, dementia caused by vascular disease, dementia associated with Parkinson's disease, dementia associated with Huntington's disease, dementia associated with alcohol addiction, Lewy body dementia and AIDS dementia;
(b) mild cognitive impairment and age-related impaired memory;
(c) dementia and/or cognitive impairment associated with epilepsy, dementia and/or cognitive impairment associated with cerebral tumor, dementia and/or cognitive impairment associated with brain injury, dementia and/or cognitive impairment associated with multiple sclerosis, dementia and/or cognitive impairment associated with Down's syndrome, dementia and/or cognitive impairment associated with Rett's syndrome, dementia and/or cognitive impairment associated with progressive supranuclear palsy, dementia and/or cognitive impairment associated with frontal lobe syndrome, and dementia and/or cognitive impairment associated with neurologic and/or psychiatric conditiones; and
(d) cognitive impairment associated with traumatic brain injury, cognitive impairment associated with aftereffects of coronary-artery bypass surgery, cognitive impairment associated with electric shock therapy and cognitive impairment associated with chemotherapy.

### Claim 21 (depends on 14, 15, 16, 17, 18, 19, 20)

A method according to any one of claims 14 to 20, wherein the patient is human.
